1 unchanged sentence
Rule 10b5-1 Trading Plans
−Removed: During the three months ended March 31, 2025, Michael McBreen , the Company’s Executive Vice President , President, Codman Specialty Surgical, adopted a trading plan intended to satisfy Rule 10b5-1(c) under the Exchange Act on March 14, 2025 to sell up to 12,000 shares of our common stock between June 13, 2025 and June 10, 2026 , the date this plan expires.
−Removed: The sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and June 10, 2026.
−Removed: Other than as disclosed above, none of the Company’s directors or officers adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K) during the three months ended March 31, 2025.
+Added: During the three months ended June 30, 2025, none of the Company’s directors or officers adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement.”
3.1(a) Amended and Restated Certificate of Incorporation of the Company dated February 16, 1993 (Incorporated by reference to Exhibit 3.1(a) to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2005)
4 unchanged sentences
3.2 Third Amended and Restated Bylaws of Integra LifeSciences Holdings Corporation, effective as of February 21, 2023 (Incorporated by reference to Exhibit 3.3 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed on February 22, 2023)
+Added: 10.1* Amendment No.
+Added: 2 to the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on May 13, 2025)
+Added: 10.2 Amendment No.
+Added: 1, dated June 6, 2025, to that Seventh Amended and Restated Credit Agreement, among Integra LifeSciences Holdings Corporation, the lenders party thereto, Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, Citibank N.A., JPMorgan Chase Bank, N.A., Morgan Stanley MUFG Loan Partners, LLC, PNC Bank, N.A., Truist Bank and Wells Fargo Bank, N.A., as Co-Syndication Agents, and The Bank of Nova Scotia, BMO Harris Bank N.A., BNP Paribas, Capital One, National Association, Citizens Bank, N.A., DNB Bank ASA, New York Branch, Santander Bank, N.A.
+Added: and TD Bank, N.A., as Co-Documentation Agents (Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on June 9, 2025)
31.1+ Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
11 unchanged sentences
+ Indicates this document is filed as an exhibit herewith.
−Removed: # The financial information of Integra LifeSciences Holdings Corporation Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed on May 5, 2025 formatted in XBRL (Extensible Business Reporting Language):
+Added: # The financial information of Integra LifeSciences Holdings Corporation Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 filed on July 31, 2025 formatted in XBRL (Extensible Business Reporting Language):
(i) the Condensed Consolidated Statements of Operations and Comprehensive Income, (ii) the Condensed Consolidated Balance Sheets, (iii) Parenthetical Data to the Condensed Consolidated Balance Sheets, (iv) the Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements, is furnished electronically herewith.
1 unchanged sentence
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
−Removed: May 5, 2025 /s/ Mojdeh Poul
+Added: July 31, 2025 /s/ Mojdeh Poul
President and Chief Executive Officer
(Principal Executive Officer)
−Removed: May 5, 2025 /s/ Lea Knight
+Added: July 31, 2025 /s/ Lea Knight
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)
−Removed: May 5, 2025 /s/ Jeffrey A.
+Added: July 31, 2025 /s/ Jeffrey A.
Senior Vice President, Finance
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.